Biotech Values

[iwfal]

ZGEN's last hurrah! - The data from the ph 2a inf-l trial:

http://www.natap.org/2010/AASLD/AASLD_53.htm

Difficult to make too much of it because the numbers are so small - and there are weird artifacts like the lower doses have higher SAE rates. But in general the trends are right with the only exception being that at the highest tested dose IFN-L required several step downs in dosing related to ALT.

PS Perhaps I missed it, but I have never seen any substantial discussion of the items published at the Nov AASLD meeting:

http://www.natap.org/2010/AASLD/AASLD.htm